SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.51-2.4%Dec 23 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: zebra4o1 who wrote (11940)6/6/2004 4:46:07 PM
From: keokalani'nui   of 52153
 
Re: ARNA.

You have to treat the preferred and the sale/leaseback obligations as debt. Also, you have to make some kind of adjustment for the enormous burn. So I would not call it 'trading at cash.'

Phase 1 single dose results will probably be over hyped in order to place the shelf. They are to be followed immediately by multi-dose P1.

ARNA may yet prove to be a great TFIF idea, but it will look much much more interesting in about 8 months.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News